Human Safety and Pharmacokinetics of the CFC Alternative Propellants HFC 134a (1,1,1,2-Tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-Heptafluoropropane) Following Whole-Body Exposure
HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol applications, including medical use in metered-dose inhalers. Production and consumption of CFCs are being phased out under the Montreal Proto...
Saved in:
| Published in | Regulatory toxicology and pharmacology Vol. 32; no. 1; pp. 22 - 35 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
San Diego, CA
Elsevier Inc
01.08.2000
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0273-2300 1096-0295 |
| DOI | 10.1006/rtph.2000.1402 |
Cover
| Abstract | HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol applications, including medical use in metered-dose inhalers. Production and consumption of CFCs are being phased out under the Montreal Protocol on Substances that Deplete the Ozone Layer. The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 h, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). Comparison of either HFC 134a or HFC 227 to CFC 12 or air gave no clinically significant results for any of the measured laboratory parameters. There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation. HFC 134a, HFC 227, and CFC 12 blood concentrations increased rapidly and in an exposure-concentration-dependent manner, although not strictly proportionally, and approached steady state. Maximum blood concentrations (Cmax) tended to be higher in males than females; in the HFC 227 study, these were statistically significantly (P < 0.05) higher in males for each HFC 227 and CFC 12 exposure level. In the HFC 134a study, the gender difference in Cmax was only statistically significant (P < 0.05) for CFC 12 at 4000 ppm and HFC 134a at 8000 ppm. Following the end of exposure, blood concentrations declined rapidly, predominantly biphasically and independent of exposure concentration. For the HFC 134a study, the t1/2α (α elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t1/2β (β elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. Mean residence time (MRT) was an overall mean of 42 and 44 min for CFC 12 and HFC 134a, respectively. In the HFC 227 study, t1/2α for both CFC 12 and HFC 227, at each exposure level, was short (<9 min) and tended to be lower in males than females. For CFC 12 mean t1/2β ranged from 23 to 43 min and for HFC 227 the mean range was 19–92 min. The values tended to be lower for females than males for HFC 227. For both CFC 12 and HFC 227, MRT was statistically significantly lower (P < 0.05) in males than females and independent of exposure concentration. For CFC 12, MRT was a mean of 37 and 45 min for males and females, respectively, and for HFC 227 MRT was a mean of 36 and 42 min, respectively. Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function. |
|---|---|
| AbstractList | HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol applications, including medical use in metered-dose inhalers. Production and consumption of CFCs are being phased out under the Montreal Protocol on Substances that Deplete the Ozone Layer. The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 h, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). Comparison of either HFC 134a or HFC 227 to CFC 12 or air gave no clinically significant results for any of the measured laboratory parameters. There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation. HFC 134a, HFC 227, and CFC 12 blood concentrations increased rapidly and in an exposure-concentration-dependent manner, although not strictly proportionally, and approached steady state. Maximum blood concentrations (C sub(max)) tended to be higher in males than females; in the HFC 227 study, these were statistically significantly (P < 0.05) higher in males for each HFC 227 and CFC 12 exposure level. In the HFC 134a study, the gender difference in C sub(max) was only statistically significant (P < 0.05) for CFC 12 at 4000 ppm and HFC 134a at 8000 ppm. Following the end of exposure, blood concentrations declined rapidly, predominantly biphasically and independent of exposure concentration. For the HFC 134a study, the t sub(1/2) alpha ( alpha elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t sub(1/2) beta ( beta elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. Mean residence time (MRT) was an overall mean of 42 and 44 min for CFC 12 and HFC 134a, respectively. In the HFC 227 study, t sub(1 /2) alpha for both CFC 12 and HFC 227, at each exposure level, was short (<9 min) and tended to be lower in males than females. For CFC 12 mean t sub(1/2) beta ranged from 23 to 43 min and for HFC 227 the mean range was 19-92 min. The values tended to be lower for females than males for HFC 227. For both CFC 12 and HFC 227, MRT was statistically significantly lower (P < 0.05) in males than females and independent of exposure concentration. For CFC 12, MRT was a mean of 37 and 45 min for males and females, respectively, and for HFC 227 MRT was a mean of 36 and 42 min, respectively. Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function. HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol applications, including medical use in metered-dose inhalers. Production and consumption of CFCs are being phased out under the Montreal Protocol on Substances that Deplete the Ozone Layer. The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 h, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). Comparison of either HFC 134a or HFC 227 to CFC 12 or air gave no clinically significant results for any of the measured laboratory parameters. There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation. HFC 134a, HFC 227, and CFC 12 blood concentrations increased rapidly and in an exposure-concentration-dependent manner, although not strictly proportionally, and approached steady state. Maximum blood concentrations (C(max)) tended to be higher in males than females; in the HFC 227 study, these were statistically significantly (P < 0. 05) higher in males for each HFC 227 and CFC 12 exposure level. In the HFC 134a study, the gender difference in C(max) was only statistically significant (P < 0.05) for CFC 12 at 4000 ppm and HFC 134a at 8000 ppm. Following the end of exposure, blood concentrations declined rapidly, predominantly biphasically and independent of exposure concentration. For the HFC 134a study, the t(1/2)alpha (alpha elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t(1/2)beta (beta elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. Mean residence time (MRT) was an overall mean of 42 and 44 min for CFC 12 and HFC 134a, respectively. In the HFC 227 study, t(1/2)alpha for both CFC 12 and HFC 227, at each exposure level, was short (<9 min) and tended to be lower in males than females. For CFC 12 mean t(1/2)beta ranged from 23 to 43 min and for HFC 227 the mean range was 19-92 min. The values tended to be lower for females than males for HFC 227. For both CFC 12 and HFC 227, MRT was statistically significantly lower (P < 0.05) in males than females and independent of exposure concentration. For CFC 12, MRT was a mean of 37 and 45 min for males and females, respectively, and for HFC 227 MRT was a mean of 36 and 42 min, respectively. Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function.HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol applications, including medical use in metered-dose inhalers. Production and consumption of CFCs are being phased out under the Montreal Protocol on Substances that Deplete the Ozone Layer. The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 h, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). Comparison of either HFC 134a or HFC 227 to CFC 12 or air gave no clinically significant results for any of the measured laboratory parameters. There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation. HFC 134a, HFC 227, and CFC 12 blood concentrations increased rapidly and in an exposure-concentration-dependent manner, although not strictly proportionally, and approached steady state. Maximum blood concentrations (C(max)) tended to be higher in males than females; in the HFC 227 study, these were statistically significantly (P < 0. 05) higher in males for each HFC 227 and CFC 12 exposure level. In the HFC 134a study, the gender difference in C(max) was only statistically significant (P < 0.05) for CFC 12 at 4000 ppm and HFC 134a at 8000 ppm. Following the end of exposure, blood concentrations declined rapidly, predominantly biphasically and independent of exposure concentration. For the HFC 134a study, the t(1/2)alpha (alpha elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t(1/2)beta (beta elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. Mean residence time (MRT) was an overall mean of 42 and 44 min for CFC 12 and HFC 134a, respectively. In the HFC 227 study, t(1/2)alpha for both CFC 12 and HFC 227, at each exposure level, was short (<9 min) and tended to be lower in males than females. For CFC 12 mean t(1/2)beta ranged from 23 to 43 min and for HFC 227 the mean range was 19-92 min. The values tended to be lower for females than males for HFC 227. For both CFC 12 and HFC 227, MRT was statistically significantly lower (P < 0.05) in males than females and independent of exposure concentration. For CFC 12, MRT was a mean of 37 and 45 min for males and females, respectively, and for HFC 227 MRT was a mean of 36 and 42 min, respectively. Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function. HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol applications, including medical use in metered-dose inhalers. Production and consumption of CFCs are being phased out under the Montreal Protocol on Substances that Deplete the Ozone Layer. The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 h, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). Comparison of either HFC 134a or HFC 227 to CFC 12 or air gave no clinically significant results for any of the measured laboratory parameters. There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation. HFC 134a, HFC 227, and CFC 12 blood concentrations increased rapidly and in an exposure-concentration-dependent manner, although not strictly proportionally, and approached steady state. Maximum blood concentrations (C(max)) tended to be higher in males than females; in the HFC 227 study, these were statistically significantly (P < 0. 05) higher in males for each HFC 227 and CFC 12 exposure level. In the HFC 134a study, the gender difference in C(max) was only statistically significant (P < 0.05) for CFC 12 at 4000 ppm and HFC 134a at 8000 ppm. Following the end of exposure, blood concentrations declined rapidly, predominantly biphasically and independent of exposure concentration. For the HFC 134a study, the t(1/2)alpha (alpha elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t(1/2)beta (beta elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. Mean residence time (MRT) was an overall mean of 42 and 44 min for CFC 12 and HFC 134a, respectively. In the HFC 227 study, t(1/2)alpha for both CFC 12 and HFC 227, at each exposure level, was short (<9 min) and tended to be lower in males than females. For CFC 12 mean t(1/2)beta ranged from 23 to 43 min and for HFC 227 the mean range was 19-92 min. The values tended to be lower for females than males for HFC 227. For both CFC 12 and HFC 227, MRT was statistically significantly lower (P < 0.05) in males than females and independent of exposure concentration. For CFC 12, MRT was a mean of 37 and 45 min for males and females, respectively, and for HFC 227 MRT was a mean of 36 and 42 min, respectively. Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function. HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol applications, including medical use in metered-dose inhalers. Production and consumption of CFCs are being phased out under the Montreal Protocol on Substances that Deplete the Ozone Layer. The safety and pharmacokinetics of HFC 134a and HFC 227 were assessed in two separate double-blind studies. Each HFC (hydrofluorocarbon) was administered via whole-body exposure as a vapor to eight (four male and four female) healthy volunteers. Volunteers were exposed, once weekly for 1 h, first to air and then to ascending concentrations of HFC (1000, 2000, 4000, and 8000 parts per million (ppm)), interspersed with a second air exposure and two CFC 12 (dichlorodifluoromethane) exposures (1000 and 4000 ppm). Comparison of either HFC 134a or HFC 227 to CFC 12 or air gave no clinically significant results for any of the measured laboratory parameters. There were no notable adverse events, there was no evidence of effects on the central nervous system, and there were no symptoms of upper respiratory tract irritation. HFC 134a, HFC 227, and CFC 12 blood concentrations increased rapidly and in an exposure-concentration-dependent manner, although not strictly proportionally, and approached steady state. Maximum blood concentrations (Cmax) tended to be higher in males than females; in the HFC 227 study, these were statistically significantly (P < 0.05) higher in males for each HFC 227 and CFC 12 exposure level. In the HFC 134a study, the gender difference in Cmax was only statistically significant (P < 0.05) for CFC 12 at 4000 ppm and HFC 134a at 8000 ppm. Following the end of exposure, blood concentrations declined rapidly, predominantly biphasically and independent of exposure concentration. For the HFC 134a study, the t1/2α (α elimination half-life) was short for both CFC 12 and HFC 134a (<11 min). The t1/2β (β elimination half-life) across all exposure concentrations was a mean of 36 and 42 min for CFC 12 and HFC 134a, respectively. Mean residence time (MRT) was an overall mean of 42 and 44 min for CFC 12 and HFC 134a, respectively. In the HFC 227 study, t1/2α for both CFC 12 and HFC 227, at each exposure level, was short (<9 min) and tended to be lower in males than females. For CFC 12 mean t1/2β ranged from 23 to 43 min and for HFC 227 the mean range was 19–92 min. The values tended to be lower for females than males for HFC 227. For both CFC 12 and HFC 227, MRT was statistically significantly lower (P < 0.05) in males than females and independent of exposure concentration. For CFC 12, MRT was a mean of 37 and 45 min for males and females, respectively, and for HFC 227 MRT was a mean of 36 and 42 min, respectively. Exposure of healthy volunteers to exposure levels up to 8000 ppm HFC 134a, 8000 ppm HFC 227, and 4000 ppm CFC 12 did not result in any adverse effects on pulse, blood pressure, electrocardiogram, or lung function. |
| Author | Emmen, H.H. Duistermaat, E. Rusch, G.M. Ravensberg, J.C. Muijser, H. Borkhataria, D. Klöpping-Ketelaars, W.A.A. Alexander, D.J. Schmit, B. Hoogendijk, E.M.G. |
| Author_xml | – sequence: 1 givenname: H.H. surname: Emmen fullname: Emmen, H.H. organization: TNO Nutrition and Food Research Institute, Zeist, The Netherlands – sequence: 2 givenname: E.M.G. surname: Hoogendijk fullname: Hoogendijk, E.M.G. organization: TNO Nutrition and Food Research Institute, Zeist, The Netherlands – sequence: 3 givenname: W.A.A. surname: Klöpping-Ketelaars fullname: Klöpping-Ketelaars, W.A.A. organization: TNO Nutrition and Food Research Institute, Zeist, The Netherlands – sequence: 4 givenname: H. surname: Muijser fullname: Muijser, H. organization: TNO Nutrition and Food Research Institute, Zeist, The Netherlands – sequence: 5 givenname: E. surname: Duistermaat fullname: Duistermaat, E. organization: TNO Nutrition and Food Research Institute, Zeist, The Netherlands – sequence: 6 givenname: J.C. surname: Ravensberg fullname: Ravensberg, J.C. organization: TNO Nutrition and Food Research Institute, Zeist, The Netherlands – sequence: 7 givenname: D.J. surname: Alexander fullname: Alexander, D.J. organization: International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-134a (IPACT-I), International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-227 (IPACT-II), Washington, DC – sequence: 8 givenname: D. surname: Borkhataria fullname: Borkhataria, D. organization: International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-134a (IPACT-I), International Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-227 (IPACT-II), Washington, DC – sequence: 9 givenname: G.M. surname: Rusch fullname: Rusch, G.M. organization: Honeywell International, Morristown, New Jersey – sequence: 10 givenname: B. surname: Schmit fullname: Schmit, B. organization: Solvay SA, Brussels, Belgium |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1514616$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11029265$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFklFrFDEUhYNU7Lb66qPkQUShsyaZmczsY126rlCwYMXHkM3cONGZZJpkaveP9feZ2V0rCEVuIIR855Dce07QkXUWEHpJyZwSwt_7OLRzRkg6FoQ9QTNKFjwjbFEeoRlhVZ6xnJBjdBLCj0Sxuq6eoWNKE8F4OUP367GXFn-RGuIWS9vgq1b6Xir301iIRgXsNI4t4OVqic-7CN7KaG4BX3k3QNdJGwNepzuaFxK_pWdTsewaope6G513EFtp4d3OfAIZqx64s3yqbA1DPNBDWjt85brO_TL2O_7Wug6yD67Z4ou7wYXRw3P0VMsuwIvDfoq-ri6ul-vs8vPHT8vzy0wVnMeM6k1T8ZyWugYFrGwkYyXIXOtaNYypuuaMVxulWKMKuVAARSkLvSBUk01d6vwUvdn7pmfdjBCi6E1Qu2-DG4OoWJ4XvKz_C9KK13lJigS-OoDjpodGDN700m_Fn5Ek4PUBkEHJTntplQl_uZIWnPKEFXtMeReCBy2UiWkyzqbGm05QIqaAiCkgYgqImAKSZPN_ZA_GjwnqvQBSm28NeBGUAaugMR5UFI0zj0l_A82Czf0 |
| CODEN | RTOPDW |
| CitedBy_id | crossref_primary_10_2169_internalmedicine_46_0185 crossref_primary_10_1016_j_molcatb_2010_07_020 crossref_primary_10_5194_acp_10_5903_2010 crossref_primary_10_1002_jat_1473 crossref_primary_10_1080_15459620701448416 crossref_primary_10_1081_CRP_62268 crossref_primary_10_1021_acssuschemeng_7b04029 crossref_primary_10_1016_j_ijd_2012_05_007 crossref_primary_10_1089_089426803764928356 crossref_primary_10_1039_C9RE00035F crossref_primary_10_1093_milmed_usy073 crossref_primary_10_1211_jpp_60_5_0004 crossref_primary_10_1016_j_jiec_2024_02_013 crossref_primary_10_1016_S0161_813X_01_00011_0 crossref_primary_10_1039_b700018a crossref_primary_10_4103_aihb_aihb_89_23 crossref_primary_10_1089_jamp_2009_0794 crossref_primary_10_1016_j_tripleo_2006_08_008 crossref_primary_10_1097_PEC_0b013e3181bedb8e crossref_primary_10_3390_molecules29020411 crossref_primary_10_1039_D1RA04536A crossref_primary_10_1016_S0378_5173_02_00086_8 crossref_primary_10_2203_dose_response_05_036_Iavicoli crossref_primary_10_1080_08958370601067905 crossref_primary_10_1097_BCR_0000000000000367 crossref_primary_10_1016_j_chemosphere_2005_03_084 crossref_primary_10_1080_10408440802237664 crossref_primary_10_1021_jacs_2c10448 crossref_primary_10_1186_s13223_017_0202_0 crossref_primary_10_1016_j_epm_2024_04_001 crossref_primary_10_1016_j_ijpharm_2008_10_025 crossref_primary_10_1016_j_mencom_2021_11_001 crossref_primary_10_1016_S0149_2918_03_80108_X crossref_primary_10_1039_D0CE01167C crossref_primary_10_1046_j_1524_4725_2001_00352_x crossref_primary_10_1093_bja_aeh154 crossref_primary_10_1016_j_toxlet_2006_08_009 crossref_primary_10_1097_01_CCM_0000220065_93507_AB crossref_primary_10_1111_anae_13551 crossref_primary_10_1097_00042728_200107000_00004 crossref_primary_10_1016_j_supflu_2012_08_017 crossref_primary_10_1016_j_toxlet_2013_11_026 crossref_primary_10_1515_polyeng_2022_0189 crossref_primary_10_1016_j_jss_2020_11_039 |
| Cites_doi | 10.3109/00498259309166779 10.1038/249810a0 10.1080/10408449991349203 10.1177/096032719501400903 10.1177/096032719501400902 10.1016/S0091-6749(98)70186-1 10.1089/jam.1995.8.Suppl_1.S-29 10.1006/faat.1995.1063 10.1111/j.2042-7158.1996.tb05980.x 10.1089/jam.1995.8.Suppl_1.S-35 |
| ContentType | Journal Article |
| Copyright | 2000 Academic Press 2000 INIST-CNRS Copyright 2000 Academic Press. |
| Copyright_xml | – notice: 2000 Academic Press – notice: 2000 INIST-CNRS – notice: Copyright 2000 Academic Press. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U7 C1K 7X8 |
| DOI | 10.1006/rtph.2000.1402 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Toxicology Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1096-0295 |
| EndPage | 35 |
| ExternalDocumentID | 11029265 1514616 10_1006_rtph_2000_1402 S0273230000914028 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Comparative Study Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 123 1B1 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5VS 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO ABEFU ABFYP ABJNI ABLST ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLECG BLXMC C45 CAG COF CS3 DM4 DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F3I F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KCYFY KOM LG5 M33 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SPT SSJ SSP SSZ T5K TEORI UHS WUQ XPP ZGI ZMT ZU3 ZXP ~G- ~KM AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH EFKBS IQODW CGR CUY CVF ECM EIF NPM 7U7 C1K 7X8 ACLOT ~HD |
| ID | FETCH-LOGICAL-c466t-1fbd76315f8ece25da225ea3ff8cd22c886267bcc2dc4a9cee45a4f901f0b85f3 |
| IEDL.DBID | AIKHN |
| ISSN | 0273-2300 |
| IngestDate | Sun Sep 28 03:05:22 EDT 2025 Thu Sep 04 22:27:11 EDT 2025 Wed Feb 19 01:21:40 EST 2025 Mon Jul 21 09:13:44 EDT 2025 Tue Jul 01 02:41:11 EDT 2025 Thu Apr 24 22:58:47 EDT 2025 Fri Feb 23 02:17:14 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Human Toxicokinetics CFC fluid Toxicity Pharmacokinetics Substitute Inhalation |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright 2000 Academic Press. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c466t-1fbd76315f8ece25da225ea3ff8cd22c886267bcc2dc4a9cee45a4f901f0b85f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 11029265 |
| PQID | 17683504 |
| PQPubID | 23462 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_72334658 proquest_miscellaneous_17683504 pubmed_primary_11029265 pascalfrancis_primary_1514616 crossref_citationtrail_10_1006_rtph_2000_1402 crossref_primary_10_1006_rtph_2000_1402 elsevier_sciencedirect_doi_10_1006_rtph_2000_1402 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2000-08-01 |
| PublicationDateYYYYMMDD | 2000-08-01 |
| PublicationDate_xml | – month: 08 year: 2000 text: 2000-08-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | San Diego, CA |
| PublicationPlace_xml | – name: San Diego, CA – name: Netherlands |
| PublicationTitle | Regulatory toxicology and pharmacology |
| PublicationTitleAlternate | Regul Toxicol Pharmacol |
| PublicationYear | 2000 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Dalby, Byron, Shepherd, Papadopoulos (RF7) 1990 Alexander (RF3) 1995; 8 Skaggs, Moore, Tapscott (RF14) 1995 Cook, Klinefelter, Hardisty, Sharpe, Foster (RF6) 1999; 29 Blumenthal, Casale, Fink, Uryniak, Casty (RF4) 1998; 101 Alexander, Libretto (RF2) 1995; 14 Ellis, Gowans, Green, Tanner (RF8) 1993; 23 Vinegar, Jepson, Cook, McCafferty, Caracci (RF17) 1997 Harrison, Donnell, Simmons, Ekholm, Cooper, Wyld (RF10) 1996; 48 Collins, Rusch, Sato, Hext, Millischer (RF5) 1995; 25 (RF9) 1995 Hermann, Ruus, Schneider, de Mey (RF11) 1998; 48 Alexander, Libretto, Chevalier, Imamura, Papprity, Wilson (RF1) 1995; 14 Ventresca (RF16) 1995; 8 Molina, Roland (RF12) 1974; 249 Pike, Aigbirhio, Freemantle, Page, Rhodes, Waters, Jones, Olsson, Ventresca, Tanner, Hayes, Hughes (RF13) 1995; 23 (RF15) 1991 Alexander (10.1006/rtph.2000.1402_RF2) 1995; 14 Pike (10.1006/rtph.2000.1402_RF13) 1995; 23 (10.1006/rtph.2000.1402_RF15) 1991 (10.1006/rtph.2000.1402_RF9) 1995 Ventresca (10.1006/rtph.2000.1402_RF16) 1995; 8 Molina (10.1006/rtph.2000.1402_RF12) 1974; 249 Blumenthal (10.1006/rtph.2000.1402_RF4) 1998; 101 Alexander (10.1006/rtph.2000.1402_RF1) 1995; 14 Hermann (10.1006/rtph.2000.1402_RF11) 1998; 48 Dalby (10.1006/rtph.2000.1402_RF7) 1990 Alexander (10.1006/rtph.2000.1402_RF3) 1995; 8 Ellis (10.1006/rtph.2000.1402_RF8) 1993; 23 Skaggs (10.1006/rtph.2000.1402_RF14) 1995 Vinegar (10.1006/rtph.2000.1402_RF17) 1997 Collins (10.1006/rtph.2000.1402_RF5) 1995; 25 Cook (10.1006/rtph.2000.1402_RF6) 1999; 29 Harrison (10.1006/rtph.2000.1402_RF10) 1996; 48 |
| References_xml | – volume: 29 start-page: 169 year: 1999 end-page: 261 ident: RF6 article-title: Rodent Leydig cell tumorigensis: A review of the physiology, pathology, mechanisms and relevance to humans publication-title: Crit. Rev. Toxicol. – year: 1995 ident: RF9 publication-title: Joint Assessment of Commodity Chemicals No. 31, 1,1,1,2-Tetrafluoroethane (HFC-134a) – volume: 249 start-page: 810 year: 1974 end-page: 812 ident: RF12 article-title: Stratospheric sink for chlorofluoromethanes: Chlorine atom catalyzed destruction of ozone publication-title: Nature – year: 1995 ident: RF14 publication-title: Toxicological Properties of Halon Substitutes – volume: 8 start-page: 35 year: 1995 end-page: 39 ident: RF16 article-title: Clinical pharmacology of HFA 134a publication-title: J. Aerosol Med. – year: 1991 ident: RF15 publication-title: Environmental Effects of Ozone Depletion – volume: 101 start-page: 7 year: 1998 end-page: 13 ident: RF4 article-title: Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial publication-title: J. Allergy Clin. Immunol. – volume: 25 start-page: 271 year: 1995 end-page: 280 ident: RF5 article-title: 1,1,1,2-Tetrafluoroethane: Repeat exposure inhalation toxicity in the rat, developmental toxicity in the rabbit, and genotoxicity publication-title: Fundam. Appl. Toxicol. – year: 1997 ident: RF17 publication-title: Human Inhalation of Halon 1301, HFC 134a and HFC 227ea for Collection of Pharmacokinetic Data – volume: 8 start-page: 29 year: 1995 end-page: 34 ident: RF3 article-title: Safety of propellants publication-title: J. Aerosol. Med. – volume: 48 start-page: 596 year: 1996 end-page: 600 ident: RF10 article-title: Twenty-eight day double-blind safety study of an HFC 134a inhalation aerosol system in healthy subjects publication-title: J. Pharm. Pharmacol. – volume: 14 start-page: 715 year: 1995 end-page: 720 ident: RF2 article-title: An overview of the toxicology of HFC 134a publication-title: Hum. Exp. Toxicol. – volume: 23 start-page: 832 year: 1995 end-page: 839 ident: RF13 article-title: Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA 134a) in healthy subjects and in patients with chronic airflow limitation publication-title: Drug Metab. Dispos. – start-page: 26 year: 1990 end-page: 33 ident: RF7 article-title: CFC propellant substitution: P-134a as a potential replacement for P-12 in MDIs publication-title: Pharm. Technol. – volume: 48 start-page: 663 year: 1998 end-page: 667 ident: RF11 article-title: Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate publication-title: Arzneimittelforschung – volume: 14 start-page: 706 year: 1995 end-page: 714 ident: RF1 article-title: HFC 134a (1,1,1,2-tetrafluoroethane): Lack of oncogenicity in rodents after inhalation publication-title: Hum. Exp. Toxicol. – volume: 23 start-page: 719 year: 1993 end-page: 729 ident: RF8 article-title: Metabolic fate and deposition of 1,1,1,2-tetrafluoroethane (HFC 134a) in the rat following a single exposure by inhalation publication-title: Xenobiotica – volume: 23 start-page: 719 year: 1993 ident: 10.1006/rtph.2000.1402_RF8 article-title: Metabolic fate and deposition of 1,1,1,2-tetrafluoroethane (HFC 134a) in the rat following a single exposure by inhalation publication-title: Xenobiotica doi: 10.3109/00498259309166779 – year: 1995 ident: 10.1006/rtph.2000.1402_RF9 – volume: 249 start-page: 810 year: 1974 ident: 10.1006/rtph.2000.1402_RF12 article-title: Stratospheric sink for chlorofluoromethanes: Chlorine atom catalyzed destruction of ozone publication-title: Nature doi: 10.1038/249810a0 – volume: 29 start-page: 169 year: 1999 ident: 10.1006/rtph.2000.1402_RF6 article-title: Rodent Leydig cell tumorigensis: A review of the physiology, pathology, mechanisms and relevance to humans publication-title: Crit. Rev. Toxicol. doi: 10.1080/10408449991349203 – volume: 14 start-page: 715 year: 1995 ident: 10.1006/rtph.2000.1402_RF2 article-title: An overview of the toxicology of HFC 134a publication-title: Hum. Exp. Toxicol. doi: 10.1177/096032719501400903 – year: 1995 ident: 10.1006/rtph.2000.1402_RF14 – volume: 48 start-page: 663 year: 1998 ident: 10.1006/rtph.2000.1402_RF11 article-title: Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate publication-title: Arzneimittelforschung – volume: 23 start-page: 832 year: 1995 ident: 10.1006/rtph.2000.1402_RF13 article-title: Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA 134a) in healthy subjects and in patients with chronic airflow limitation publication-title: Drug Metab. Dispos. – year: 1991 ident: 10.1006/rtph.2000.1402_RF15 – volume: 14 start-page: 706 year: 1995 ident: 10.1006/rtph.2000.1402_RF1 article-title: HFC 134a (1,1,1,2-tetrafluoroethane): Lack of oncogenicity in rodents after inhalation publication-title: Hum. Exp. Toxicol. doi: 10.1177/096032719501400902 – volume: 101 start-page: 7 year: 1998 ident: 10.1006/rtph.2000.1402_RF4 article-title: Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial publication-title: J. Allergy Clin. Immunol. doi: 10.1016/S0091-6749(98)70186-1 – year: 1997 ident: 10.1006/rtph.2000.1402_RF17 – volume: 8 start-page: 29 year: 1995 ident: 10.1006/rtph.2000.1402_RF3 article-title: Safety of propellants publication-title: J. Aerosol. Med. doi: 10.1089/jam.1995.8.Suppl_1.S-29 – volume: 25 start-page: 271 year: 1995 ident: 10.1006/rtph.2000.1402_RF5 article-title: 1,1,1,2-Tetrafluoroethane: Repeat exposure inhalation toxicity in the rat, developmental toxicity in the rabbit, and genotoxicity in vitro and in vivo publication-title: Fundam. Appl. Toxicol. doi: 10.1006/faat.1995.1063 – start-page: 26 year: 1990 ident: 10.1006/rtph.2000.1402_RF7 article-title: CFC propellant substitution: P-134a as a potential replacement for P-12 in MDIs publication-title: Pharm. Technol. – volume: 48 start-page: 596 year: 1996 ident: 10.1006/rtph.2000.1402_RF10 article-title: Twenty-eight day double-blind safety study of an HFC 134a inhalation aerosol system in healthy subjects publication-title: J. Pharm. Pharmacol. doi: 10.1111/j.2042-7158.1996.tb05980.x – volume: 8 start-page: 35 year: 1995 ident: 10.1006/rtph.2000.1402_RF16 article-title: Clinical pharmacology of HFA 134a publication-title: J. Aerosol Med. doi: 10.1089/jam.1995.8.Suppl_1.S-35 |
| SSID | ssj0002887 |
| Score | 1.8461142 |
| Snippet | HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol... HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) are used to replace chlorofluorocarbons (CFCs) in refrigerant and aerosol... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 22 |
| SubjectTerms | 1,1,1,2,3,3,3-Heptafluoropropane 1,1,1,2-Tetrafluoroethane Administration, Inhalation Adult Aerosol Propellants - pharmacokinetics Atmosphere Exposure Chambers Biological and medical sciences Blood Pressure - drug effects Chemical and industrial products toxicology. Toxic occupational diseases Chlorofluorocarbons, Methane - adverse effects Chlorofluorocarbons, Methane - pharmacokinetics Dose-Response Relationship, Drug Double-Blind Method Electrocardiography Female Gas, fumes Half-Life Humans Hydrocarbons, Fluorinated - pharmacokinetics Inhalation Exposure Male Medical sciences Respiratory Function Tests Safety Sex Characteristics Toxicology |
| Title | Human Safety and Pharmacokinetics of the CFC Alternative Propellants HFC 134a (1,1,1,2-Tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-Heptafluoropropane) Following Whole-Body Exposure |
| URI | https://dx.doi.org/10.1006/rtph.2000.1402 https://www.ncbi.nlm.nih.gov/pubmed/11029265 https://www.proquest.com/docview/17683504 https://www.proquest.com/docview/72334658 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW27gVpQjC-Cmz4AQ2Q6rXxR-I-lmpVADFVWif2FsWOLU1USdSmQF_4Wfw-rmO31ST6gvKU5MRxkpN7j2_iexF6awyMKSSPiBYmIXxYFAScgiKx1FwYBZpEuXjH16s4veGfb8XtARpv5sK43yqD7fc2vbXWYUs_3M1-fXfXv3aZWEBAO5UAowQqD9ERBW8vO-ho9OlLerU1yFS2dfIcnrgDNrkbB3F_0dTtFwlY5SGy8g_fdFznS7hj1pe62K9FW580eYQeBjGJR76_j9GBKU_Q-dRno1738Gw3uWrZw-d4ustTvT5Bxz5kh_1MpCfoTxvQx9e5Nc0a52WxxX8HKerawJXFIBjxeDLGo3kIJf4weOoi-sCnslniFPZFjOf4fdRzCyUz0yxyO19Vi8q4QL350DbugJQmW1yPuYWkpm4CGq6_buETIGv1E5ws_ubK-ZKPVbHGl7_qyoU3n6KbyeVsnJJQ1oFoHscNiawqwKpFwkqjDRVFDjbF5MxaqQtKtXSDrERpTQvN8yF4cS5ybkG42IGSwrJnqFNWpXmBcGILIa2SGprikWWKgeBMzICBzGKFUF1ENg800yHnuSu9Mc98tuY4cwRwpThhFQjQRe-2-Npn-9iLjDb8yO7xNQNXtPeY03tE2p1CuOrqcRe92RArg5dctw_OVKtlFsGgkIkB349IKGMc1GQXPfeM3DUOEnJIY_HyP3r8Cj3wqQfcD4-vUadZrMwpiLBGnaHDi9_RWXjV_gLWTi7- |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6V9ABShaC8ApTuARWQskq8D9s5hqiRS9soUlPRm-Vd70oVkW0lDpA_xu9jxo9ElcgF-WT783ptf575duydIeSjtTCmCKXHjLIBk8M0ZeAUNPNDI5XVoEk0xjuup350K7_dqbsDMm7nwuBvlY3tr216Za2bLf3mbvaL-_v-DWZiAQGNKgFGCTx8RA4lFrXukMPRxWU03RpkHlZ18hDP8IA2d-PA7y_LovoiAauyiaz8wzcdFckK7pirS13s16KVT5o8I08bMUlHdX-fkwObHZOzWZ2NetOj893kqlWPntHZLk_15pgc1SE7Ws9EekH-VAF9epM4W25okqVb_A-QotgGzR0FwUjHkzEdLZpQ4k9LZxjRBz5l5YpGsM8TMqGfvR4unM1tuUzcYp0vc4uBevulahyBnAdbXE_gwiJblA0arr-o4BMga_4LnCz9juV82dc83dDz30WO4c2X5HZyPh9HrCnrwIz0_ZJ5Tqdg1TzlQmssV2kCNsUmwrnQpJybEAdZgTaGp0YmQ_DiUiXSgXBxAx0qJ16RTpZn9g2hgUtV6HRooCnpOaEFCM7ADgTILJEq3SWsfaCxaXKeY-mNRVxna_ZjJACW4oRVIECXfNriizrbx16k1_IjfsDXGFzR3mNOHhBpdwqF1dX9LjltiRXDS26qB2fz9Sr2YFAo1EDuRwRcCAlqskte14zcNQ4Scsh99fY_enxKHkfz66v46mJ6-Y48qdMQ4M-P70mnXK7tCQiyUn9oXri_9Icw5A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+safety+and+pharmacokinetics+of+the+CFC+alternative+propellants+HFC+134a+%281%2C1%2C1%2C2-tetrafluoroethane%29+and+HFC+227+%281%2C1%2C1%2C2%2C3%2C3%2C+3-heptafluoropropane%29+following+whole-body+exposure&rft.jtitle=Regulatory+toxicology+and+pharmacology&rft.au=Emmen%2C+H+H&rft.au=Hoogendijk%2C+E+M&rft.au=Kl%C3%B6pping-Ketelaars%2C+W+A&rft.au=Muijser%2C+H&rft.date=2000-08-01&rft.issn=0273-2300&rft.volume=32&rft.issue=1&rft.spage=22&rft_id=info:doi/10.1006%2Frtph.2000.1402&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0273-2300&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0273-2300&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0273-2300&client=summon |